Remacemide
Remacemide (FPL 12924) is an orally active, non-competitive, low-affinity NMDA receptor antagonist. Remacemide shows neuroprotection activity in animal models of hypoxia and ischemic stroke. Remacemide is also an anticonvulsant, and can be used in Parkinson's disease and Huntington's disease research[1][2][3][4].
Product Specifications
CAS Number
128298-28-2
Product Name Alternative
FPL 12924; PR 934-423; FPL 13592
UNSPSC
12352005
Target
IGluR
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel; Neuronal Signaling
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/remacemide.html
Purity
99.88
Solubility
DMSO : 87.5 mg/mL (ultrasonic)
Smiles
O=C(CN)NC(C)(CC1=CC=CC=C1)C2=CC=CC=C2
Molecular Formula
C17H20N2O
Molecular Weight
268.35
References & Citations
[1]Schachter SC, et al. Remacemide: current status and clinical applications. Expert Opin Investig Drugs. 2000 Apr;9 (4) :871-83.|[2]Dyker AG, et al. Remacemide hydrochloride: a double-blind, placebo-controlled, safety and tolerability study in patients with acute ischemic stroke. Stroke. 1999 Sep;30 (9) :1796-801.|[3]Greenamyre JT, et al. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann Neurol. 1994 Jun;35 (6) :655-61. |[4]Kieburtz K, et al. A controlled trial of remacemide hydrochloride in Huntington's disease. Mov Disord. 1996 May;11 (3) :273-7.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
NMDA Receptor
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
